Ranolazine + Placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Chronic Stable Angina

Conditions

Chronic Stable Angina

Trial Timeline

Dec 1, 2013 → Oct 10, 2016

NCT ID

NCT01948310

About Ranolazine + Placebo

Ranolazine + Placebo is a approved stage product being developed by Gilead Sciences for Chronic Stable Angina. The current trial status is completed. This product is registered under clinical trial identifier NCT01948310. Target conditions include Chronic Stable Angina.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03044964	Approved	UNKNOWN	Jan 10, 2017	Oct 1, 2017	Angina
NCT02829034	Approved	Completed	Jul 1, 2016	Jan 1, 2018	Pulmonary Hypertension
NCT02423265	Approved	Withdrawn	Jun 1, 2015	Mar 1, 2017	Myocardial Ischemia
NCT02147067	Phase 2	Completed	Sep 1, 2014	Jun 1, 2018	Microvascular Angina
NCT02156336	Approved	Terminated	May 1, 2014	Feb 8, 2017	Diabetic Peripheral Neuropathic Pain
NCT02052011	Approved	Completed	Apr 1, 2014	Nov 1, 2015	Microvascular Angina
NCT01948310	Approved	Completed	Dec 1, 2013	Oct 10, 2016	Chronic Stable Angina
NCT01887353	Phase 2	Terminated	Jun 1, 2013	Feb 1, 2014	Atrial Fibrillation
NCT01767987	Phase 2	Terminated	Nov 1, 2012	Apr 1, 2014	Acute Coronary Syndrome
NCT01590979	Pre-clinical	Terminated	Apr 1, 2012	Jun 1, 2015	Atrial Fibrillation New Onset
NCT01558830	Approved	UNKNOWN	Jan 1, 2012	Jul 1, 2013	Chronic Stable Angina
NCT01472185	Phase 3	Completed	Nov 1, 2011	Oct 1, 2013	Type 2 Diabetes Mellitus
NCT01442038	Phase 3	Completed	Oct 1, 2011	Feb 1, 2015	Coronary Artery Disease
NCT01505179	Pre-clinical	Completed	Feb 1, 2011	Jan 1, 2015	Heart Failure With Preserved Ejection Fraction
NCT01352416	Phase 3	Terminated	Sep 1, 2010	Nov 1, 2012	Heart; Dysfunction Postoperative, Cardiac Surgery
NCT01163721	Phase 2	Completed	Jun 1, 2010	Nov 1, 2010	Diabetes Mellitus, Type 2
NCT00832572	Approved	Terminated	Jan 1, 2009	Jun 1, 2009	Coronary Artery Disease
NCT00099788	Phase 3	Completed	Oct 1, 2004	Feb 1, 2007	Myocardial Ischemia

Competing Products

20 competing products in Chronic Stable Angina

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved